RyboDyn raised $10 million in seed funding to accelerate its efforts to decode the dark proteome for oncology target discovery. The company combines deep sequencing of non-canonical RNAs with proteome detection, feeding findings into its CypherAtlas database for AI-assisted target prioritization. RyboDyn said its dataset includes data from roughly 1,000 patient tumors across multiple cancer indications and mass-spectrometry characterization of thousands of cryptic peptides, including cancer-specific targets. The company also reported in vitro killing linked to a cryptic protein target and outlined plans to translate discoveries into IND-enabling work. The financing reflects continued investor appetite for platform plays that claim patient-derived target discovery at scale, particularly when they can point to functional validation rather than discovery alone.